This inventor holds 44 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Thrombopoietin Mimetics. Top assignees: Smithkline Beecham Corporation, Glaxosmithkline LLC, Glaxosmithkline Intellectual Property (No.2) Limited. Active years: 1994-2021.
Location History:
- Audubon, PA (US) (1994 - 2005)
- King of Prussia, PA (US) (2009)
- Collegeville, PA (US) (2005 - 2021)
Company Filing History:
32 out of 2,198 
5 out of 358 
2 out of 95 
Years Active: 1994-2021
Areas of Expertise:
Title: The Innovative Contributions of Juan I Luengo
Introduction
Juan I Luengo, based in Audubon, PA, is a prolific inventor with an impressive portfolio of 44 patents. His work primarily focuses on pharmaceutical innovations, particularly in the field of cancer research and treatment. Luengo's inventions aim to develop effective compounds for the inhibition of specific enzymes implicated in various diseases, including cancer.
Latest Patents
Among his latest innovations, Juan I Luengo has developed several noteworthy patents. One significant invention is titled "Substituted pyridines as inhibitors of DNMT1." This invention addresses the need for selective inhibitors of DNMT1, which may hold therapeutic potential for treating cancer, pre-cancerous syndromes, sickle cell disease, sickle cell anemia, and other disorders associated with DNMT1 inhibition. The compounds are designed in accordance with a specific formula, offering pharmaceutical compositions that contain these compounds.
In addition, Luengo has made strides in the enhancement of cancer treatment with his patent for "Enhancer of zeste homolog 2 inhibitors." This invention includes novel compounds that inhibit EZH2 and offers pharmaceutical formulations of these inhibitors, positioning them as promising agents in cancer therapy.
Career Highlights
Throughout his career, Juan I Luengo has collaborated with prominent organizations such as SmithKline Beecham Corporation and GlaxoSmithKline LLC. His extensive experience in these pharmaceutical giants has provided him with the knowledge and resources necessary to advance his research and innovations in the field of cancer therapies.
Collaborations
Luengo has worked alongside esteemed colleagues, including Kevin J. Duffy and John Duncan Elliott. Their collaborations have contributed significantly to the development of new therapeutic compounds, further enhancing the potential impact of their joint research efforts.
Conclusion
Juan I Luengo exemplifies the spirit of innovation in the pharmaceutical field. With 44 patents to his name and ongoing research into critical therapies for diseases like cancer, his contributions significantly impact medical science. Through his work, Luengo continues to push the boundaries of what is possible in drug development and disease treatment.